All News

Blog: I’ll be Leonardo and so much more

June 25, 2022

In a profession that values super subspecialization, combined with a society that pigeonholes physicians into corners, I often felt I didn’t fit into one job title with my varied passions and cross interests.

RegeneRx licensee to expand Phase 3 clinical trial program with RGN-259

June 24, 2022

RegeneRx Biopharmaceuticals Inc. said its U.S. joint venture partner and licensee, HLB Therapeutics, will expand its ophthalmic clinical development program with RGN-259 in two indications, neurotrophic keratopathy and dry eye disease.

How quality vision builds a foundation for safety and everyday activities

June 22, 2022

As ophthalmologists observe Cataract Awareness Month this June, William L. Soscia, MD, medical director at Center for Sight, in Sarasota, Florida, focuses on the importance of having excellent vision for safety and everyday functions.

Bausch + Lomb receives permanent J-Code for triamcinolone acetonide injectable suspension

June 21, 2022

The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.

Foundation Fighting Blindness announces leadership changes

June 21, 2022

Jason Menzo is named CEO, while Russell Kelley, PhD, MBA, will become managing director of the RD Fund. Ben Yerxa, PhD, will take the helm of Opus Genetics, the first RD Fund- and foundation-backed spin-off company.